ADA2018: Insulet Reports Positive Clinical Results For Omnipod Horizon, Limited Market Release Of Dash
Insulet Corp. plans a limited market release in the second half of this year of its recently FDA-cleared Omnipod Dash Insulin Management System through the pharmacy channel. Results from the most recent clinical trial supporting the Omnipod hybrid closed-loop system were presented this week's American Diabetes Association meeting in Orlando.
You may also be interested in...
Market Intel: Rivalry Among Insulin Pump Makers Heats Up With Expected Launches In 2021
The global insulin pump market is expected to see double-digit growth, reaching $5.1bn in 2024, with product launches expected by Medtronic, Insulet, Tandem and smaller players in 2021.
No Easy Task But Insulet Determined To Fly Solo In Europe
After eight years together, Insulet will be splitting from its exclusive European distributor Ypsomed and take full responsibility for the distribution, sales, marketing, training and support activities of its Omnipod insulin management system in that region. Insulet's president and chief operating officer, Shacey Petrovic told Medtech Insight how the Massachusetts-based company will embark on this next solo chapter.
Insulet, Ypsomed Split Up And Go Head-To-Head In Insulin Pump Market
Insulin pump commercial partners Insulet and Ypsomed will be parting ways after some eight years in an exclusive distribution alliance. The companies failed to reach an agreement to renew the distributor agreement, which will end June 2018, following differences on price. Ypsomed announced it will introduce its own tubeless insulin pump in the mid-term.